Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Effect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be-CLEVER)
Phase 3
Recruiting
- Conditions
- StrokePost-stroke Cognitive Impairment (PSCI)
- Interventions
- Drug: dl-3-butylphthalideDrug: dl-3-butylphthalide placebo
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 3200
- Registration Number
- NCT05976152
- Locations
- 🇨🇳
Donggang Center Hospitol, Dandong, Liaoning, China
Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 20
- Registration Number
- NCT05976932
Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer
Phase 2
Active, not recruiting
- Conditions
- Colorectal Cancer
- Interventions
- Drug: FOLFIRI+Bevacizumab
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT05969899
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Fudan University, Shanghai, Pudong, China
PET-CT Predicting Segement Specific Lymph Nodes Metastasis
Recruiting
- Conditions
- Lymph Node MetastasisPositron Emission TomographyNon Small Cell Lung Cancer
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 280
- Registration Number
- NCT05970913
- Locations
- 🇨🇳
Shanghai Cancer Center, Shanghai, China
Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC
Phase 2
Recruiting
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 101
- Registration Number
- NCT05970705
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Phase II Study of Sufantinib Combined With AG Versus AG First-line in the Treatment of LAPC or mPC
Phase 2
Not yet recruiting
- Conditions
- Pancreatic Neoplasms
- Interventions
- Drug: Sofantinib、abraxane、gemcitabine
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 65
- Registration Number
- NCT05969171
- Locations
- 🇨🇳
Fudan University ShangHai Cancer Center, Shanghai, China
Suture Repair vs Mesh Repair in the Treatment of Incarcerated Groin Hernia in Elderly Populations
Not yet recruiting
- Conditions
- Incarcerated Groin Hernia
- Interventions
- Other: mesh repairOther: suture repair
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 70
- Registration Number
- NCT05966285
A Longitudinal Study of the Trajectory of Financial Toxicity and Its Relationship With Symptom Burden in Breast Cancer Patients
Active, not recruiting
- Conditions
- Financial Toxicity
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 485
- Registration Number
- NCT05964816
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shenyang, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, China
🇨🇳Wuhan Union Hospital, Wuhan, China
Regorafenib Alone or in Combination With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Microsatellite Stable Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 90
- Registration Number
- NCT05963490
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer
Phase 3
Recruiting
- Conditions
- High-risk Stage II Colorectal CancerStage III Colorectal CancerCirculating Tumor DNA Methylation
- Interventions
- Drug: mFOLFIRINOX adjuvant chemotherapyDrug: mFOLFOX6/XELOX adjuvant chemotherapy
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 340
- Registration Number
- NCT05954078
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath